Nagourney Cancer Institute

The Nagourney Cancer Institute is a personalized medicine center specializing in functional profiling to identify the most effective chemotherapy treatments for individual cancer patients. Utilizing their proprietary Ex Vivo Programmed Cell Death (EVA) assay, the institute tests live tumor cells against various drug combinations to measure real-time response and cell death. This approach shifts the focus from genomic sequencing to functional proteomics, aiming to improve survival rates by selecting treatments based on actual phenotypic drug sensitivity. The institute provides diagnostic services for a wide range of solid and hematologic malignancies, helping oncologists tailor therapies to the unique biology of each patient's tumor. Their research focuses on identifying synergistic drug combinations and overcoming drug resistance in advanced cancers.